A new investigational drug, from Eisai and Biogen, has shown promising results for slowing progression of cognitive decline during Phase 3 clinical trial.
1,795 individuals diagnosed with early Alzheimer's disease were enrolled in the study and the drug slowed disease progression by 27% compared to the placebo.
lecanemab is a monoclonal antibody which targets amyloid build-up in the brain, which is then cleared by the immune system. It is believed that memory loss and confusion associated with Alzheimer's is caused by a build-up of amyloid in the brain which can contribute to brain cells being killed.
Alzheimer's is a degenerative brain disease, which sadly many of us will have experienced the effects of. Progress by the Pharma sector in slowing or even one day curing this awful disease is a wonderful thing!
Initial results of a Phase 3 clinical trial of lecanemab announced late Tuesday are being hailed by some as a “major milestone” in Alzheimer’s disease treatments. Japanese drugmaker Eisai and U.S. biotechnology company Biogen on Tuesday announced the positive results from the Clarity AD clinical trial of lecanemab. It is an investigational anti-amyloid beta antibody in the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzhemier’s disease. Results will be presented Nov. 29 at the Clinical Trials on Alzheimer’s Congress. “These are the most encouraging results in clinical trials treating the underlying causes of Alzheimer’s to date,” Alzheimer’s Association President Joanne Pike, DrPH, said in announcing the results. “These results indicate lecanamab may give people more time at or near their full abilities to participate in daily life, remain independent and make future healthcare decisions.”
unknownx500
